Jazz Pharmaceuticals plc (JAZZ) Debt Components
- 2026-06-30: Long-term Debt, Current MaturitiesUSD $1.02B; Long-term Debt, Excluding Current MaturitiesUSD $3.33B; Long-term DebtUSD $4.35B; Long-Term Debt, Maturity, Year OneUSD $31.00M.
- 2026-03-31: Long-term Debt, Current MaturitiesUSD $1.03B; Long-term Debt, Excluding Current MaturitiesUSD $4.32B; Long-term DebtUSD $5.35B; Long-Term Debt, Maturity, Year OneUSD $31.00M.
- 2025-12-31: Long-term Debt, Current MaturitiesUSD $1.03B; Long-term Debt, Excluding Current MaturitiesUSD $4.33B; Long-term DebtUSD $5.36B; Long-Term Debt, Maturity, Year OneUSD (m).
- 2025-12-31: Long-term Debt, Current MaturitiesUSD (m); Long-term Debt, Excluding Current MaturitiesUSD (m); Long-term DebtUSD (m); Long-Term Debt, Maturity, Year OneUSD $1.03B.
Jazz Pharmaceuticals plc Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Long-term Debt, Current Maturities USD | Long-term Debt, Excluding Current Maturities USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-Term Debt, Maturity, Year Five USD | Long-Term Debt, Maturity, after Year Five USD | Long-Term Debt, Maturity, Remainder of Fiscal Year USD | Long-term Debt, Gross USD | Secured Debt, Current USD | Secured Debt USD | Long-term Line of Credit USD | Line of Credit Facility, Maximum Borrowing Capacity USD | Long-term Debt, Fair Value USD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.02B | $3.33B | $4.35B | $31.00M | $1.85B | $1.50B | $1.00B | (m) | (m) | $15.50M | $4.39B | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $1.03B | $4.32B | $5.35B | $31.00M | $1.85B | $1.50B | $1.00B | (m) | (m) | $1.02B | $5.40B | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $1.03B | $4.33B | $5.36B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | (m) | $1.03B | $31.00M | $1.85B | $1.50B | $1.00B | (m) | (m) | $5.41B | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $1.03B | $4.33B | $5.36B | $1.03B | $31.00M | $1.85B | $1.50B | (m) | (m) | $7.75M | $5.42B | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $1.03B | $4.34B | $5.36B | $1.03B | $31.00M | $1.85B | $1.50B | (m) | (m) | $15.50M | $5.43B | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $31.00M | $5.34B | $5.37B | $1.03B | $31.00M | $1.85B | $1.50B | (m) | (m) | $23.25M | $5.43B | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $31.00M | $6.08B | $6.11B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | (m) | (m) | (m) | $31.00M | $1.03B | $31.00M | $2.60B | $1.50B | $1.00B | (m) | $6.19B | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $31.00M | $6.08B | $6.11B | $31.00M | $1.03B | $31.00M | $2.60B | (m) | (m) | $7.75M | $6.20B | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $605.80M | $5.10B | $5.71B | $31.00M | $1.03B | $31.00M | $2.60B | (m) | (m) | $590.50M | $5.78B | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $605.38M | $5.11B | $5.71B | $31.00M | $1.03B | $31.00M | $2.60B | (m) | (m) | $598.25M | $5.79B | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $604.95M | $5.11B | $5.71B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | (m) | (m) | (m) | $606.00M | $31.00M | $1.03B | $31.00M | $2.60B | $1.50B | (m) | $5.80B | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $604.51M | $5.11B | $5.72B | $606.00M | $31.00M | $1.03B | $31.00M | (m) | (m) | $7.75M | $5.81B | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $31.00M | $5.69B | $5.72B | $606.00M | $31.00M | $1.03B | $31.00M | (m) | (m) | $15.50M | $5.81B | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $31.00M | $5.69B | $5.72B | $606.00M | $31.00M | $1.03B | $31.00M | (m) | (m) | $23.25M | $5.82B | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $31.00M | $5.69B | $5.72B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | (m) | (m) | (m) | $31.00M | $606.00M | $31.00M | $1.03B | $31.00M | $4.10B | (m) | $5.83B | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $31.00M | $5.70B | $5.73B | $31.00M | $606.00M | $31.00M | $1.03B | (m) | (m) | $7.75M | $5.84B | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $31.00M | $5.99B | $6.02B | $31.00M | $606.00M | $31.00M | $1.03B | (m) | (m) | $15.50M | $6.14B | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $31.00M | $5.99B | $6.02B | $31.00M | $606.00M | $31.00M | $1.03B | (m) | (m) | $23.25M | $6.15B | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $31.00M | $6.02B | $6.05B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | (m) | (m) | $31.00M | $31.00M | $606.00M | $31.00M | $1.03B | $4.67B | (m) | $6.40B | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $31.00M | $6.25B | $6.28B | $31.00M | $31.00M | $606.00M | $31.00M | (m) | (m) | $7.75M | $6.65B | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $248.59M | $6.49B | $6.74B | $31.00M | $31.00M | $606.00M | $31.00M | (m) | (m) | $234.31M | $7.14B | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $248.61M | $1.85B | $2.10B | $33.39M | $517.49M | $575.00M | $0.00 | (m) | (m) | $243.85M | $2.37B | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $246.32M | $1.85B | $2.09B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | (m) | (m) | $252.20M | $33.39M | $517.49M | $575.00M | (m) | (m) | (m) | $2.38B | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $244.00M | $1.84B | $2.09B | $252.20M | $33.39M | $517.49M | $575.00M | (m) | (m) | $8.35M | $2.39B | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $33.39M | $2.07B | $2.10B | $275.50M | $33.39M | $517.49M | $575.00M | (m) | (m) | $16.69M | $2.42B | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $33.39M | $1.58B | $1.61B | (m) | $608.39M | $33.39M | $517.49M | $575.00M | (m) | $25.04M | $1.76B | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $33.39M | $1.57B | $1.61B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | (m) | $33.39M | $608.39M | $33.39M | $517.49M | $575.00M | (m) | (m) | $1.77B | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $33.39M | $1.57B | $1.60B | (m) | $33.39M | $608.39M | $33.39M | $517.49M | $575.00M | $8.35M | $1.78B | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $33.39M | $1.57B | $1.60B | $33.39M | $608.39M | $33.39M | $517.49M | (m) | $575.00M | $16.69M | $1.78B | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $33.39M | $1.57B | $1.60B | $33.39M | $608.39M | $33.39M | $517.49M | (m) | $575.00M | $25.04M | $1.79B | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $33.39M | $1.56B | $1.60B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | (m) | $33.39M | $33.39M | $608.39M | $33.39M | $517.49M | $575.00M | (m) | $1.80B | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $33.39M | $1.56B | $1.59B | (m) | $33.39M | $33.39M | $608.39M | $33.39M | $1.09B | $8.35M | $1.81B | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $33.39M | $1.56B | $1.59B | (m) | $33.39M | $33.39M | $608.39M | $33.39M | $1.09B | $16.69M | $1.82B | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $45.12M | $1.54B | $1.58B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $40.60M | $1.54B | $1.58B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | (m) | $40.60M | $58.65M | $76.70M | $1.08B | (m) | $575.00M | (m) | $1.83B | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $36.09M | $1.54B | $1.58B | (m) | $40.61M | $58.65M | $76.70M | $1.08B | $575.00M | $9.02M | $1.84B | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $36.09M | $1.64B | $1.67B | (m) | $40.61M | $58.65M | $76.70M | $1.58B | (m) | $18.05M | $1.77B | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $136.09M | $1.74B | $1.88B | (m) | $40.60M | $58.65M | $76.70M | $1.78B | (m) | $27.07M | $1.98B | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $36.09M | $1.99B | $2.03B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | (m) | (m) | $36.09M | $40.61M | $58.65M | $76.70M | $1.93B | (m) | (m) | $2.14B | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $36.09M | $2.15B | $2.18B | (m) | $36.09M | $40.61M | $58.65M | $76.70M | $2.08B | $9.02M | $2.30B | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $37.50M | $1.14B | $1.18B | (m) | $42.19M | $60.94M | $79.69M | $520.31M | $575.00M | $18.75M | $1.30B | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $37.59M | $1.15B | $1.18B | (m) | $42.28M | $61.04M | $79.79M | $520.45M | $575.00M | $28.19M | $1.31B | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $37.59M | $1.15B | $1.19B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | (m) | (m) | $37.59M | $42.28M | $61.03M | $79.79M | $520.42M | $575.03M | (m) | $1.32B | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $117.59M | $1.17B | $1.29B | (m) | $37.59M | $42.28M | $61.04M | $79.79M | $1.18B | $9.40M | $1.41B | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $28.48M | $1.34B | $1.37B | (m) | $37.85M | $42.55M | $61.17M | $79.79M | $1.26B | $9.68M | $1.49B | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $9.39M | $1.33B | $1.34B | (m) | $9.39M | $9.40M | $868.45M | $101.00K | $575.13M | $7.11M | $1.47B | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $9.43M | $1.33B | $1.34B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | (m) | (m) | $9.43M | $9.43M | $9.44M | $868.48M | $114.00K | $575.15M | (m) | $1.47B | (m) | (m) | $0.00 | (m) | (m) |
| 2014-09-30 | $9.44M | $1.33B | $1.34B | $2.44M | $9.45M | $9.45M | $9.46M | $868.49M | $575.27M | (m) | $1.47B | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $9.47M | $1.19B | $1.20B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $9.51M | $1.19B | $1.20B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $5.57M | $544.40M | $549.98M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $5.57M | $545.56M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $5.57M | $546.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $32.66M | $418.51M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $29.69M | $427.07M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | $26.72M | $435.63M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $23.75M | $444.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-12 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $575.00M | (m) |
| 2011-12-31 | $0.00 | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | $0.00 |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $32.69M | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $16.06M | $40.69M | (m) | (m) | $40.86M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |